Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 126


Photodynamic vaccination of hamsters with inducible suicidal mutants of Leishmania amazonensis elicits immunity against visceral leishmaniasis.

Kumari S, Samant M, Khare P, Misra P, Dutta S, Kolli BK, Sharma S, Chang KP, Dube A.

Eur J Immunol. 2009 Jan;39(1):178-91. doi: 10.1002/eji.200838389.


Elongation factor-2, a Th1 stimulatory protein of Leishmania donovani, generates strong IFN-γ and IL-12 response in cured Leishmania-infected patients/hamsters and protects hamsters against Leishmania challenge.

Kushawaha PK, Gupta R, Sundar S, Sahasrabuddhe AA, Dube A.

J Immunol. 2011 Dec 15;187(12):6417-27. doi: 10.4049/jimmunol.1102081. Epub 2011 Nov 11.


Intracellular replication-deficient Leishmania donovani induces long lasting protective immunity against visceral leishmaniasis.

Selvapandiyan A, Dey R, Nylen S, Duncan R, Sacks D, Nakhasi HL.

J Immunol. 2009 Aug 1;183(3):1813-20. doi: 10.4049/jimmunol.0900276. Epub 2009 Jul 10.


Th1-stimulatory polyproteins of soluble Leishmania donovani promastigotes ranging from 89.9 to 97.1 kDa offers long-lasting protection against experimental visceral leishmaniasis.

Kumari S, Samant M, Misra P, Khare P, Sisodia B, Shasany AK, Dube A.

Vaccine. 2008 Oct 23;26(45):5700-11. doi: 10.1016/j.vaccine.2008.08.021. Epub 2008 Aug 30.


Delta-aminolevulinate-induced host-parasite porphyric disparity for selective photolysis of transgenic Leishmania in the phagolysosomes of mononuclear phagocytes: a potential novel platform for vaccine delivery.

Dutta S, Chang C, Kolli BK, Sassa S, Yousef M, Showe M, Showe L, Chang KP.

Eukaryot Cell. 2012 Apr;11(4):430-41. doi: 10.1128/EC.05202-11. Epub 2012 Feb 3.


Prophylactic efficacy of high-molecular-weight antigenic fractions of a recent clinical isolate of Leishmania donovani against visceral leishmaniasis.

Tripathi P, Gupta SK, Sinha S, Sundar S, Dube A, Naik S.

Scand J Immunol. 2008 Nov;68(5):492-501. doi: 10.1111/j.1365-3083.2008.02171.x. Epub 2008 Sep 18.


Long-lasting protection against canine visceral leishmaniasis using the LiESAp-MDP vaccine in endemic areas of France: double-blind randomised efficacy field trial.

Lemesre JL, Holzmuller P, Gonçalves RB, Bourdoiseau G, Hugnet C, Cavaleyra M, Papierok G.

Vaccine. 2007 May 22;25(21):4223-34. Epub 2007 Mar 15.


Enhanced efficacy and immunogenicity of 78kDa antigen formulated in various adjuvants against murine visceral leishmaniasis.

Nagill R, Kaur S.

Vaccine. 2010 May 21;28(23):4002-12. doi: 10.1016/j.vaccine.2010.01.015. Epub 2010 Jan 19.


Recombinant Leishmania tarentolae expressing the A2 virulence gene as a novel candidate vaccine against visceral leishmaniasis.

Mizbani A, Taheri T, Zahedifard F, Taslimi Y, Azizi H, Azadmanesh K, Papadopoulou B, Rafati S.

Vaccine. 2009 Dec 10;28(1):53-62. doi: 10.1016/j.vaccine.2009.09.114. Epub 2009 Oct 8.


Leishmania infantum HSP70-II null mutant as candidate vaccine against leishmaniasis: a preliminary evaluation.

Carrión J, Folgueira C, Soto M, Fresno M, Requena JM.

Parasit Vectors. 2011 Jul 27;4:150. doi: 10.1186/1756-3305-4-150.


Efficacy of Leishmania donovani trypanothione reductase, identified as a potent Th1 stimulatory protein, for its immunogenicity and prophylactic potential against experimental visceral leishmaniasis.

Khare P, Jaiswal AK, Tripathi CD, Joshi S, Sundar S, Dube A.

Parasitol Res. 2014 Mar;113(3):851-62. doi: 10.1007/s00436-013-3716-5. Epub 2013 Dec 27.


Characterization of glycolytic enzymes--rAldolase and rEnolase of Leishmania donovani, identified as Th1 stimulatory proteins, for their immunogenicity and immunoprophylactic efficacies against experimental visceral leishmaniasis.

Gupta R, Kumar V, Kushawaha PK, Tripathi CP, Joshi S, Sahasrabuddhe AA, Mitra K, Sundar S, Siddiqi MI, Dube A.

PLoS One. 2014 Jan 24;9(1):e86073. doi: 10.1371/journal.pone.0086073. eCollection 2014.


gp63 in stable cationic liposomes confers sustained vaccine immunity to susceptible BALB/c mice infected with Leishmania donovani.

Bhowmick S, Ravindran R, Ali N.

Infect Immun. 2008 Mar;76(3):1003-15. doi: 10.1128/IAI.00611-07. Epub 2008 Jan 14.


Immunization with the DNA-encoding N-terminal domain of proteophosphoglycan of Leishmania donovani generates Th1-type immunoprotective response against experimental visceral leishmaniasis.

Samant M, Gupta R, Kumari S, Misra P, Khare P, Kushawaha PK, Sahasrabuddhe AA, Dube A.

J Immunol. 2009 Jul 1;183(1):470-9. doi: 10.4049/jimmunol.0900265.


Treatment of Leishmania donovani-infected hamsters with miltefosine: analysis of cytokine mRNA expression by real-time PCR, lymphoproliferation, nitrite production and antibody responses.

Gupta R, Kushawaha PK, Samant M, Jaiswal AK, Baharia RK, Dube A.

J Antimicrob Chemother. 2012 Feb;67(2):440-3. doi: 10.1093/jac/dkr485. Epub 2011 Nov 25.


Induction of cellular and humoral responses by autoclaved and heat-killed antigen of Leishmania donovani in experimental visceral leishmaniasis.

Nagill R, Mahajan R, Sharma M, Kaur S.

Parasitol Int. 2009 Dec;58(4):359-66. doi: 10.1016/j.parint.2009.07.008. Epub 2009 Jul 26.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk